REaCT
REthinking Clinical Trials

REaCT-BTA

REaCT-BTA	Frequency of treatment of bone targeted agents (every 4 weeks vs every 12 weeks) for patients with metastatic breast cancer or castration-resistant prostate cancer Principal Investigator(s): Dr. Mark Clemons
ClinicalTrials.gov: NCT02721433
Defining the optimal dosing interval of bone-targeted agents (BTA) for patients with bone metastases is an important question. This trial is comparing 4- versus 12-weekly therapy with any commonly used bone-targeted agent in patients with either metastatic breast or prostate cancer. This study has completed accrual and Year 2 follow up in ongoing.
Sites: Cancer Centre of Southeastern Ontario (Kingston) Cross Cancer Institute (Edmonton) London Health Sciences Centre The Ottawa Hospital Thunder Bay Regional Health Sciences Centre
Tags: Castration-resistant prostate cancer Metastatic breast cancer
Publications: Systematic Review: Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis. Ibrahim et al, 2015. PMID: 26122727 De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis. Awan et al, 2019. PMID: 31079283 Patient and Physician Surveys: Bone-targeted agent use for bone metastases from breast cancer and prostate cancer: A patient survey. Hutton et al, 2013. PMID: 26909279 De-escalated administration of bone-targeted agents in patients with breast and prostate cancer-A survey of Canadian oncologists. Hutton et al, 2013. PMID: 26909274 Commentary and Meeting Abstracts: Dosing Strategies of Bone-Targeting Agents. Hutton et al, 2015. PMID: 26524744 The ZOOM trial: more boon than doom? Hutton et al, 2013. PMID: 23993380 A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer. Clemons et al, 2019. ASCO 2019 Abstract 11501 Clinical Trial results: A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer. Clemons et al, 2020. PMID: 33023785 Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer. Clemons et al. 2021 PMID: 34567960